BEIGENE (06160) rose over 3%, as of the time of this report, it increased by 3.28% to 110.1 Hong Kong dollars, with a transaction volume of 0.162 billion Hong Kong dollars.
According to Zhitung Finance APP, BEIGENE (06160) rose over 3%, as of the time of this report, it increased by 3.28% to 110.1 Hong Kong dollars, with a transaction volume of 0.162 billion Hong Kong dollars.
On the evening of December 27, BEIGENE announced that the USA Food and Drug Administration (FDA) has approved Bai Ze An (Tislelizumab) in combination with platinum and fluorouracil-based chemotherapy for adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer expressing PD-L1 (≥1) as first-line treatment. The new indication is based on the results of a Global phase 3 trial, which demonstrated that Bai Ze An combined with chemotherapy can significantly improve overall survival in patients with advanced gastric cancer. It is reported that this is the second approval granted to Bai Ze An by the FDA in 2024.
